Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
LABT
vs
S&P 500
LABT
S&P 500
Over the past 12 months, LABT has underperformed S&P 500, delivering a return of -90% compared to S&P 500's +16% growth.
Stocks Performance
LABT vs S&P 500
Performance Gap
LABT vs S&P 500
Performance By Year
LABT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Lakewood-Amedex Biotherapeutics Inc
Glance View
Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. The company is headquartered in University Park, Florida and currently employs 5 full-time employees. The company went IPO on 2026-04-23. The firm is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The firm is engaged in development of its Bisphosphocin class of antimicrobial agents. The firm is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The firm has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.